Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Ordinary shares, par value 0.002 GBP per share
-
Shares outstanding
-
147,336,360
-
Total 13F shares
-
124,913,742
-
Share change
-
+481,479
-
Total reported value
-
$1,797,461,231
-
Put/Call ratio
-
501%
-
Price per share
-
$14.38
-
Number of holders
-
130
-
Value change
-
-$6,439,174
-
Number of buys
-
73
-
Number of sells
-
52
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) as of Q1 2025
As of 31 Mar 2025,
Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
124,913,742 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, Index Venture Life Associates VI Ltd, GENERAL ATLANTIC, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., JANUS HENDERSON GROUP PLC, PRICE T ROWE ASSOCIATES INC /MD/, First Light Asset Management, LLC, FARALLON CAPITAL MANAGEMENT LLC, Avoro Capital Advisors LLC, and FMR LLC.
This page lists
130
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.